The Real-World Israeli Experience of Treating Chronic Hepatitis C, Genotype 1 Patients with Advanced Fibrosis with Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir with or without Ribavirin: A Large Multi-Center Cohort

Zuckerman, Elimelech; Ashkenasi, E.; Kovalev, Yulia; Weitsman, E.; Kaspa, Ran Tur; Brown, M.; Cohen, Michal; Saadi, Tarek; Baruch, Yehuda; Carlebach, Matthias; Hazzan, Rawi; Safadi, Rifaat; Goldberg, Tova; Oren, Ran; Ashur, Yaffa; Carmiel, Michal; Kitay, Y; Hadari, Ruth; Mouch, Saif Abu; Menachem, Yoram; Kathcman, H.; Bruk, Rafael; Shibolet, Oren

doi:10.1016/s0168-8278(16)01641-x

Cited by 26 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of PrOD with and without ribavirin was reported in several real‐life cohorts in Europe and the United States. The overall SVR rates ranged from 93% to 99% comparable to that of the registration studies . In this real‐life cohort of 41 patients in Hong Kong, the SVR of PrOD with or without ribavirin (95.1%) was comparable to that reported in registration studies in the West.…”

Section: Discussionsupporting

confidence: 72%

“…The overall SVR rates ranged from 93% to 99% comparable to that of the registration studies. [9][10][11][12] In this real-life cohort of 41 patients in Hong Kong, the SVR of PrOD with or without ribavirin (95.1%) was comparable to that reported Real-life hepatitis C treatment in Hong Kong in registration studies in the West. The antiviral treatment was generally well tolerated with no hepatic decompensation reported.…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Chan

Tsang

Hui

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 71%

Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Chan

Tsang

Hui

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Another group of 22 liver transplant patients were treated with this regimen after transplantation in an Israeli study. The SVR rate in this study was 86% and there were no adverse events …”

Section: Transplant Recipients Also Have Excellent Response Ratessupporting

confidence: 46%

Hepatitis C: efficacy and safety in real life

Flisiak

Pogorzelska

Flisiak-Jackiewicz

2017

Liver International

View full text Add to dashboard Cite

Interferon-free combinations were registered in 2014 and 2015 for the treatment of chronic HCV infection. As a result, real-world experience has been gathered in the last year and this paper presents data available in September 2016. Real-world studies on the efficacy of the ledipasvir/sofosbuvir (LDV/SOF)±ribavirin (RBV) regimen showed a sustained virologic response (SVR) rate of between 91% and 98%. The SVR rate in the 13858 patients included in this paper was 94%, and 92% in the 3506 patients with cirrhosis. In a number of recently published real-world studies evaluating ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±RBV, the SVR rate was between 92% and 100%. The SVR rate of the 4260 patients included in the studies in this paper was 97% and the rate was the same in the 1647 patients with cirrhosis. Recently, data evaluating SOF/simeprevir±RBV showed an SVR rate >90%, while in combination with daclatasvir this rate reached approximately 95%. The safety data available for LDV/SOF±RBV and OBV/PTV/r±DSV±RBV show that discontinuation due to adverse events was necessary in no more than 3% of patients and the frequency of serious adverse events was between 0 and 11%, in particular in real-world studies. Because of the similar efficacy and safety, real-world data support the use of either the LDV/SOF±RBV or OBV/PTV/r±DSV±RBV regimen in patients with genotypes 1 or 4. There is still not enough real-world data in patients with genotype 3 and other genotypes.

show abstract

“…The C‐SALT study, a phase 2, non‐randomized, open‐label trial, investigating the fixed‐dose combination of elbasvir (50 mg) and grazoprevir (100 mg) (hereafter elbasvir/grazoprevir) for 12 weeks reported one death due to progressive liver failure and 2 relapses in a total of 30 genotype 1‐infected patients with CTP class B cirrhosis . Similarly, the combination of dasabuvir plus ombitasvir/paritaprevir/ritonavir should not be administered due to increased risk of hepatic decompensation . Recently, the daily fixed‐dose combinations of glecaprevir (300 mg) and pibrentasvir (120 mg) (hereafter glecaprevir/pibrentasvir), as well as sofosbuvir (400 mg), velpatasvir (100 mg) and voxilaprevir (100 mg) (hereafter sofosbuvir/velpatasvir/voxilaprevir) were approved for HCV treatment .…”

Section: Therapy Regimens In Patients With Decompensated Cirrhosismentioning

confidence: 99%

Managing hepatitis C in patients with the complications of cirrhosis

Mücke

Lange

et al. 2018

Liver International

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is still a major global health problem resulting in significant morbidity and mortality.1 The introduction of direct acting antivirals (DAA) has revolutionized HCV treatment and eradication can now be obtained in most patients. | THERAPY REGIMENS IN PATIENTS WITH DECOMPENSATED CIRRHOSISCurrent guidelines recommend urgent antiviral treatment in HCVinfected patients with significant fibrosis or cirrhosis. However, K E Y W O R D Sdecompensated cirrhosis, difficult-to-treat patients, hepatitis C virus, hepatocellular carcinoma

show abstract

The Real-World Israeli Experience of Treating Chronic Hepatitis C, Genotype 1 Patients with Advanced Fibrosis with Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir with or without Ribavirin: A Large Multi-Center Cohort

Cited by 26 publications

References 0 publications

Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Hepatitis C: efficacy and safety in real life

Managing hepatitis C in patients with the complications of cirrhosis

Contact Info

Product

Resources

About